MedPath

Aztreonam

Generic Name
Aztreonam
Brand Names
Azactam, Cayston
Drug Type
Small Molecule
Chemical Formula
C13H17N5O8S2
CAS Number
78110-38-0
Unique Ingredient Identifier
G2B4VE5GH8
Background

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.

Indication

For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.

Associated Conditions
Bone and Joint Infections, Cystic Fibrosis (CF), Febrile Neutropenia, Gynecological Infection, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Osteomyelitis, Septic Arthritis, Septicemia, Skin Infections, Urinary Tract Infection, Uncomplicated Gonorrhea
Clinical Trials
Related News

Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

Not Applicable
Recruiting
Conditions
Carbapenem-Resistant Enterobacteriaceae Infection
Interventions
Other: Conventional treatment
First Posted Date
2023-05-09
Last Posted Date
2023-05-09
Lead Sponsor
Qianfoshan Hospital
Target Recruit Count
427
Registration Number
NCT05850871
Locations
🇨🇳

Mingju Hao, Jinan, Shandong, China

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Phase 1
Recruiting
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
First Posted Date
2023-03-21
Last Posted Date
2025-04-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT05777603
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

Phase 1
Completed
Conditions
Bacterial Infection
Interventions
Drug: Ceftazidime-Avibactam
First Posted Date
2019-06-06
Last Posted Date
2022-06-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
48
Registration Number
NCT03978091
Locations
🇺🇸

Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States

Aztreonam for Pharyngeal Gonorrhea

Phase 2
Completed
Conditions
Gonorrhea of Pharynx
Gonorrhea
Interventions
First Posted Date
2019-03-08
Last Posted Date
2022-01-18
Lead Sponsor
University of Washington
Target Recruit Count
32
Registration Number
NCT03867734
Locations
🇺🇸

Public Health -- Seattle & King County STD Clinic, Seattle, Washington, United States

Nebulized Aztreonam for Prevention of Gram Negative Ventilator-associated Pneumonia

Phase 2
Terminated
Conditions
Ventilator Associated Pneumonia
Prevention
Respiratory Infection Other
Interventions
Device: Aerogen Solo
Device: CombiHaler
First Posted Date
2018-11-21
Last Posted Date
2021-07-01
Lead Sponsor
Hospital Universitari Joan XXIII de Tarragona.
Target Recruit Count
9
Registration Number
NCT03749226
Locations
🇪🇸

Critical Care Department - Hospital Universitario de Tarragona Joan XXIII, Tarragona, Spain

Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Phase 2
Recruiting
Conditions
Bronchiectasis Adult
Interventions
Other: Placebo
First Posted Date
2018-10-04
Last Posted Date
2023-04-18
Lead Sponsor
University of Dundee
Target Recruit Count
100
Registration Number
NCT03696290
Locations
🇬🇧

Manchester University NHS Foundation Trust - Wythenshawe Hospital, Manchester, United Kingdom

🇬🇧

Cardiff & Vale University Local Health Board, Cardiff, United Kingdom

🇬🇧

NHS Lanakrshire University Hospital Hairmyres, East Kilbride, United Kingdom

and more 11 locations

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Piperacillin/tazobactam
First Posted Date
2017-12-18
Last Posted Date
2018-01-05
Lead Sponsor
Spero Therapeutics
Target Recruit Count
27
Registration Number
NCT03376529
Locations
🇬🇧

Simbec Research, Ltd., Merthyr Tydfil,, Mid Glamorgan, United Kingdom

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Phase 3
Terminated
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization
Cystic Fibrosis
Interventions
Drug: Placebo
First Posted Date
2017-07-17
Last Posted Date
2022-06-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
149
Registration Number
NCT03219164
Locations
🇧🇪

UZ Antwerpen, Edegem, Belgium

🇮🇱

Rambam Health Corporation, Haifa, Israel

🇮🇱

Lady Davis Carmel Medical Center, Haifa, Israel

and more 50 locations

The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas

Phase 4
Terminated
Conditions
Tracheostomy Infection
Interventions
First Posted Date
2017-05-17
Last Posted Date
2021-07-30
Lead Sponsor
UCSF Benioff Children's Hospital Oakland
Target Recruit Count
5
Registration Number
NCT03158116
Locations
🇺🇸

Benioff Children's Hospital Oakland, Oakland, California, United States

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

Phase 4
Completed
Conditions
Infection
Cystic Fibrosis
Pseudomonas
Interventions
Drug: Standard Care
First Posted Date
2016-09-09
Last Posted Date
2019-10-07
Lead Sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Target Recruit Count
16
Registration Number
NCT02894684
Locations
🇬🇧

Liverpool Heart & Chest Hospital NHS Trust, Liverpool, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy